Investigation of the Therapeutic Potential of NSAIDs and Medicinal Cannabis (THC and CBD) in the Modulation of PAF-AH and sPLA2 Enzymes in U87 Glioblastoma Cells.

• Grant number: 24/20886-8
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: June 01, 2025
• End date: December 31, 2025
• Field of knowledge: Biological Sciences - Pharmacology - Biochemical and Molecular Pharmacology
• Principal Investigator: Marcos Hikari Toyama
• Grantee: Paloma Peixoto Borges
• Host Institution: Instituto de Biociências (IB-CLP). Universidade Estadual Paulista (UNESP). Campus Experimental do Litoral Paulista. São Vicente , SP, Brazil

Abstract

Glioblastoma multiforme (GBM) is an aggressive brain cancer with high inflammation levels that promote tumor growth and treatment resistance. The enzymes platelet-activating factor acetylhydrolase (PAF-AH) and secretory phospholipase A2 (sPLA2) play key roles in the GBM microenvironment, contributing to tumor progression. This study explores the inhibitory potential of non-steroidal anti-inflammatory drugs (NSAIDs) and medicinal cannabis compounds (THC and CBD) on these enzymes using U87 glioblastoma cells. The research involves silico modeling, in vitro enzymatic assays, and cell culture experiments to assess drug interactions, enzymatic inhibition, and cellular responses. Additionally, the study investigates the potential synergy between these compounds and conventional therapies.Findings from this study may provide insights into novel therapeutic strategies to improve GBM treatment outcomes.